AVXL vs DNLI
AVXL: Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple Alzheimer's and Parkinson's trials. DNLI: Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the blood-brain barrier for the treatment of neurodegenerative diseases and rare disorders.
Side-by-side fundamentals
| Metric | AVXL | DNLI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.55 | $23.64 | |
| Market cap as of 2026-07-23 | $234M | $3.7B | |
| PEG as of 2026-07-23 | n/a | -1.05 | |
| Net margin as of 2026-07-23 | n/a | -36.5% | |
| Operating margin as of 2026-07-23 | n/a | -49.7% | |
| ROE as of 2026-07-23 | -38.8% | -50.1% | AVXL higher |
| ROA as of 2026-07-23 | -35.0% | -44.2% | AVXL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | AVXL lower |
| Beta as of 2026-07-23 | 1.15 | 0.99 | |
| 1-year return as of 2026-07-22 close | -77.1% | +72.3% | DNLI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.